GleamWall
中文EN

RGBP Regen BioPharma Inc

Pharmaceutical Preparations · OTC · SEC CIK 1589150 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.0%
TTM net income YoY-54.5%
TTM EPS YoY77.8%
Revenue 3-yr CAGR15.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-339.8%
Net margin-501.4%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-489.7%
ROIC (approx.)—
Asset turnover0.98x

Leverage & solvency

Liabilities / assets2,144.0%
Debt / equity—
Current ratio0.05x
Interest coverage-4.72x

Cash quality & payout

Operating cash flow / net income0.38x
Accruals ratio-305.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-09-30FY20242024-09-30
Income statement
Revenue$236,561$236,560
R&D expense$11,725$153,685
SG&A expense$75,113$58,920
Operating income-$338,540-$417,221
Interest expense$158,286$72,445
Pretax income-$1.27M-$668,255
Income tax$0$0
Net income-$1.27M-$668,255
EPS (basic)-0.05-0.16
EPS (diluted)-0.05-0.16
Weighted avg. shares (diluted)23.52M4.11M
Balance sheet
Cash & equivalents$69,555$716
Receivables$204,873$94,873
Current assets$274,628$143,351
Total assets$274,628$161,084
Current liabilities$6.56M$5.38M
Total liabilities$6.56M$5.38M
Shareholders' equity-$6.28M-$5.22M
Shares outstanding39.37M5.26M
Cash flow statement
Operating cash flow-$383,591-$751,536
Financing cash flow$452,430$631,215
Stock-based compensation—$13,048

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.